메뉴 건너뛰기





Volumn 20, Issue 3, 2015, Pages 245-246

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PILARALISIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

EID: 84925409338     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0449     Document Type: Article
Times cited : (31)

References (0)
  • Reference 정보가 존재하지 않습니다.

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.